Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A

Development of inhibitors to factor VIII (FVIII) occurs in approximately 30% of severe hemophilia A (HA) patients. These patients are treated with bypassing agents (activated prothrombin complex concentrate [aPCC] and recombinant activated FVII-rFVIIa). Recently, a bispecific FIX/FIXa- and FX/FXa-di...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, Yanan, Antovic, Aleksandra, Soutari, Nida Mahmoud Hourani, Antovic, Jovan, Pruner, Iva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373667/
https://www.ncbi.nlm.nih.gov/pubmed/32704613
http://dx.doi.org/10.1055/s-0040-1710032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373667/
https://www.ncbi.nlm.nih.gov/pubmed/32704613
http://dx.doi.org/10.1055/s-0040-1710032

Ejemplares similares